TBPHTheravance Biopharma, Inc.

$716M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M-2.0% YoY

Gross Profit

-$699,000-4.8% margin

Operating Income

-$17M-119.0% margin

Net Income

-$10M-70.7% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

+17.7%

Cash Flow

Operating Cash Flow

-$124M

Free Cash Flow

-$124M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$607M

Total Liabilities

$166M

Stockholders' Equity

$442M

Cash & Equivalents

$298M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$15M	-2.0%
Gross Profit	-$699,000	-$16M	+95.7%
Operating Income	-$17M	-$56M	+69.0%
Net Income	-$10M	-$32M	+67.7%

Revenue Segments

Viatris collaboration agreement

$15M100%

Collaboration revenue

$5,0000%

TBPH Q4 2022 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena